A Review: Monoclonal Antibodies and their Applications in Medicine and Beyond

Suchitra S. Mishra*, Mohini Ninave, Namrata Gavhankar, Ankitkumar Barele,
Sanika Atkare, Shubhangi Ghuge, Vishal Jadhao
Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, MS, 440037, India

Corresponding Author
Suchitra Mishra
Dadasaheb Balpande College of Pharmacy,
Nagpur, MS, 440037, India.

Abstract

Conventional treatments for various diseases confront challenges associated with them such as, Non-specific targeting, Limited efficacy, Development of resistance Immunosuppression and Toxicity leading to thoughtful side impacts. Monoclonal antibodies (mAbs) have revolutionized the field of pharmaceutical, offering targeted therapies for numerous diseases. This review offers a comprehensive exploration of the development, mechanisms and uses of monoclonal antibodies (mAbs). This review incorporates the discussion on the structural and functional properties of mAbs, their production methodologies, various clinical applications of mAbs, and the various conjugation strategies utilized to improve their therapeutic efficacy. The review highlights the clinical applications of mAbs in oncology, immunology, as well as infectious diseases, as well as their emerging roles in neurology, ophthalmology, and cardiovascular medication. Additionally, we explore the use of mAbs in diagnostic imaging, gene therapy, and as biosensors. The challenges and future bearings of mAb development, counting the potential of bispecific antibodies, are also discussed. This comprehensive review points to provide a thorough understanding of the existing state and future perspective of mAbs in medicine and beyond.

Keywords: Monoclonal Antibodies, non-specific targeting, immunosuppression, diagnostic imaging, biosensor, gene therapy, oncology.

Introduction

The immune system can be broadly classified into two primary defense mechanisms: innate immunity and adaptive immunity. Innate immunity serves as the body's first line of defense against invading pathogens. It is a non-specific, antigen-independent mechanism that responds immediately or within hours of encountering an antigen. [1]. Antibodies, also referred to as immunoglobins, play a crucial role in the humoral immune Response. They exist in different forms, ranging from natural antibodies derived from humans or mice to engineered versions such as chimeric, humanized, and fragmented antibodies, developed through protein engineering. [2]. Monoclonal antibodies are highly specific protein molecules produced using hybridoma technology and recombinant DNA techniques to mimic the immune system's response against foreign invaders. Each monoclonal antibody is specific antibody that binds exclusively to its particular epitope (a short amino acid sequence of the antigen to which the antibody bind) [1]. Compared to polyclonal antibodies, monoclonal antibodies offer greater precision due to standardized production methods and consistent affinity for their target antigens.

In therapeutic applications, a particular monoclonal antibody is referred to as Mab. Mabs are derived from the vast array of antibodies naturally produced by the immune system to combat foreign substances. Advances in mAb technology have enabled the large-scale production of highly purified antibodies designed to target specific antigens, facilitating the development of novel diagnostic tools and treatment strategies. When administered into the bloodstream, these antibodies specifically seek out their intended disease target, enhancing precision in disease treatment. [3].

Molecular Structure

Antibodies are complex biomolecules composed of four polypeptide chains, consisting of two identical light chains and two identical heavy chains. The fully assembled antibody has an approximate molecular weight of 15kD and is shaped like a "Y" (fig. 1) [4,7]. The light chains weigh around 25kDa, while the heavy chains are approximately 50kDa. Each chain consists of distinct regions, including both variable and



Figure 1. Structure of an Antibody

constant regions. The most variable part of heavy chain is the HCDR3 (heavy-chain complementarity determining region 3) [5]. VH (heavy chain) and VL (light chain), the variable domains, contain complementarity- determining. The antibody structure can be categorized into two primary sections: The Fab (antigen- binding fragment) and the Fc (fragment crystallizable) regions. The Fab regions, positioned at the arms of the "Y" contain the variable domains responsible for antigen recognition. In contrast, the Fc region, situated at the stem of the "Y", dictates the antibody's class and is involved in various effector functions. The Fab region includes CDRs, which allow for high-affinity binding to specific antigen epitopes. The heavy chain forms the constant region at the base of the "Y", while the light chain forms the variable region on the arms, which is key to antigen recognition [6].

Mechanism of Action of Monoclonal Antibodies

1. **Antibody- dependent cellular cytotoxicity (ADCC):**

Antibody- dependent cellular cytotoxicity (ADCC) is an essential process through which antibodies help to eliminate tumour cells. During this process, antibodies bind to both tumour cells and immune cells, aiding in the destruction of the targeted cells [8,9]. The variable regions of antibodies specifically recognize antigens on the surface of tumour cells, while the Fc region interacts with Fcγ receptors found on the immune cells, like natural killer (NK) cells. Tafasitamab, a recently approved monoclonal antibody, targets

CD19, a protein expressed on B-cells surface as they mature. CD19 is also overexpressed in certain B-cell related tumours, making it a valuable target for treatment. To enhance its ADCC activity, Tafasitamab has been engineered with two amino acid changes (S239D and I332E) in its Fc region, improving its ability to bind to Fcγ receptors. This modification not only boosts ADCC but also enhances antibody- dependent cellular phagocytosis (ADCP) [10]. By utilizing these mechanisms, Tafasitamab shows potent anti-tumour activity.

2. 2. Complement- mediated cytotoxicity(CMC)

Many monoclonal antibodies (mAbs) used in cancer therapy, particularly those of the IgG1 isotype, have the ability to trigger the complement classical pathway (CDC). This occurs when IgG1 antibodies bind to tumour-specific antigens on the target cell's surface, which in turn recruits the C1q protein to the Fc region of the antibody. This interaction initiates a proteolytic cascade that eventually forms the membrane attack complex (MAC) through the activation and assembly of complement factors, including poly-C9 [11]. Some therapeutic mAbs, like Rituximab, can also enhance immune responses by prompting antibody-dependent cellular cytotoxicity (ADCC) and antibody-

dependent cellular phagocytosis (ADCP). In addition to these activities, these mAbs can also trigger CDC, contributing to the elimination of cancer cells. Another monoclonal antibody, Naxitamab, specifically targets the glycolipid GD2, which is overexpressed in neuroblastoma and other neuroectodermal tumors. In laboratory studies, Naxitamab has been shown to bind to GD2 on the surface of target cells, triggering both CDC and ADCC [12].



Figure 2. Mechanism of action of Monoclonal antibodies

3. Antibody- dependent cellular phagocytosis (ADCC)

ADCP is an important immune mechanism that relies on the interaction between the Fc region of antibodies and the FcγRI receptor found on macrophages, neutrophils and eosinophiles. Through this process, antibodies bind to tumour cells, facilitating their recognition, internalization and subsequent degradation within phagosomes. Studies indicate thaantibodies known for inducing antibody-dependent cellular cytotoxicity (ADCC), such as Tafasitamab, also have the capacity to trigger ADCP. This response is linked to the release of gamma-interferon (IFN-γ) by NK cells, that enhances FcγRI expression on polymorphonuclear cells, thereby promoting phagocytosis activity [13,69]. Additionally, certain antibodies like Daratumumab can initiate multiple immune-mediated mechanisms against cancer cells, including ADCC, ADCP, complement-dependent cytotoxicity (CDC), apoptosis, and the regulation of CD38 enzyme functions. Daratumumab, specifically targets the CD38 antigen, present on multiple myeloma cells as well as some normal lymphoid and myeloid cells.

4. Modulating the cytokine environment

Antibodies play vital role in regulating the immune response by modulating cytokine production and activity. This process occurs when antibodies bind to specific antigens on immune or tumour cells, initiating a series of signaling events that target immune molecules like PD-1/PD-L1 or CTLA-4 can alter cytokine levels, affecting immune cell activation and proliferation. These antibodies can shift the balance between pro-inflammatory cytokines, including TNF- α and IL-6, and anti-inflammatory cytokines, such as IL-10. Additionally, modifying the cytokine environment can significantly impact anti-tumor immunity. Antibodies directed at tumor necrosis factor receptor superfamily member 9 (TNFRSF9) can regulate cytokines that facilitate the

recruitment and activation of immune cells like T cells and natural killer cells, within the tumor microenvironment. By shaping cytokine production and activity, antibodies can either enhance or suppress immune responses, ultimately influencing the success of cancer immunotherapy.

4. Agonism of immune receptors

Monoclonal antibodies can influence the immune response by acting as agonists to immune receptors, initiating signaling cascade that activates immune cells. This process occurs when these antibodies bind to specific receptors found on immune cells, like T cells or NK cells. By mimicking the natural ligand, the antibody induces a structural change in the receptor, triggering intracellular signaling cascades. This activation promotes immune cell proliferation, differentiation and enhanced function, strengthening the immune response against cancer cells, pathogens or other foreign invaders.

Types of Monoclonal Antibodies

Antibodies are of different types, ranging from fully unaltered antibodies derived from mice (murine) or humans to altered types such as chimeric, humanized, and fragmented antibodies which are produced through protein engineering techniques (Fig.2).

1. Murine monoclonal antibodies

Murine monoclonal antibodies (mAbs), derived from rats and mice of the Muridae family, belong to the IgG class. Structurally, they resemble human antibodies, consisting of two light chains and two heavy chains arranged in a Y-shaped structure. These were the first monoclonal antibodies to be produced in laboratories using hybridoma technology, first developed in 1975. Murine mAbs have been instrumental in advancing modern antibody production techniques and expanding the potential applications of artificial immunoglobulins in both therapeutic and analytical fields [14].

In medicine, murine mAbs have served as foundational models for antibody engineering, leading to advancements such as humanization, chimerization, and the development of bispecific antibodies derived from single-chain antibody fragments. Preclinical studies have also explored their use in targeting capsular polysaccharides and enhancing the therapeutic efficacy of amphotericin B. Therapeutic agents based on murine mAbs are typically identified by the "-omab" suffix in their names [5].

2. Chimeric monoclonal antibodies

Chimeric antibodies are therapeutic antibodies created by combining genetic components from both human and non-human sources, such as mice. This process involves merging the variable regions from one species, like mice, with the constant regions of another species, such as humans. By engineering the human constant region alongside the mouse variable region, these antibodies are designed to be approximately 65%



Figure 3. Types of Monoclonal antibodies

human in composition, reducing the likelihood of immune system reactions to foreign proteins [18]. Chimeric monoclonal antibodies are developed to lower immunogenicity and extend serum half-life, making them more effective for therapeutic applications. Despite the genetic modifications, they maintain the original antibody's antigen specificity and binding affinity. Medications based on chimeric antibodies can be recognized by the "-ximab" suffix in their names [67], with examples including infliximab, rituximab, and abciximab [18,68].

3. Humanized monoclonal antibodies

Humanized antibodies are genetically engineered to i integrate the advantages of both human and murine antibodies. They consist mainly of human antibody sequences, with murine hypervariable regions incorporated into the variable domains. Due to their compatibility with the human immune system, humanized monoclonal antibodies (HMAs) are considered safe for in vivo applications and are often regarded as natural drugs.

Building upon the foundation of chimeric monoclonal antibodies, HMAs replace most murine-derived regions with human sequences, except for the complementarity-determining regions (CDRs), which are responsible for antigen binding. This design retains the antibody's specificity while minimizing immune system recognition of foreign proteins. Humanized antibodies contain only small murine

protein components within a human protein framework [15]. Several FDA-approved humanized monoclonal antibodies include daclizumab, omalizumab, and alemtuzumab, all of which can be identified by the "-zumab" suffix [18,70].

4. Human monoclonal antibodies

Fully human monoclonal antibodies (mAbs) are proteins that have been engineered through molecular biological methods so as to modify their amino acid sequences. These alterations improve their specificity, affinity, or biological functions, introducing sequences not typically occur in the human immune system. Therapeutic human mAbs are usually recognized by the "-umab" suffix in their names.

Producing fully human mAbs through conventional hybridoma technology presents challenges, as maintaining immortalized human cell lines is stressful and difficult. Additionally, in vivo immunization of humans with a wide range of antigens is not practical, unlike the use of animal models [9]. An alternative approach involves displaying antibody fragments on filamentous bacteriophages, allowing for the screening of antibody [19,20]. The development of fully human mAbs offers a viable solution for generating low-immunogenic therapeutic antibodies without the need for re-engineering murine mAbs [16,18]. Notable FDA-approved human mAbs include Panitumumab® and Adalimumab®, with many others currently undergoing clinical trials [17].

Production of Monoclonal Antibodies

This method involves selecting a specific myeloma cell line based on its ability to grow in tissue culture capable of producing monoclonal antibodies. As the polyclonal antibodies are mixture of various types of antibodies, monoclonal antibodies produced from a single hybridoma line are chemically identical. These highly targeted antibodies are derived from a single clone of B cells. The process includes fusing B-lymphocytes with myeloma cells in the laboratory. While myeloma cells use the de novo pathway for DNA synthesis, B-lymphocytes rely on the salvage pathway for DNA replication [21].

The salvage pathway relies on Hypoxanthine-Guanine Phosphoribosyl Transferase (HGPRT) as its essential enzyme. When the B-lymphocytes and mutated cells are cultured in medium supplemented with Hypoxanthine-Aminopterin-Thymidine (HAT), De novo synthesis gets blocked and thus the myeloma cells may die. Only B-lymphocytes as well as fused hybrid cells known as hybridomas can survive and continue to grow under these conditions. Hybridoma cells grow because they possess the HGPRT gene from lymphocytes obtained from fused B-cells, which lacks in myeloma cells [21].

The myeloma cell line selected in this process is specifically chosen for its ability to grow in tissue culture while lacking the capacity to produce antibodies. Monoclonal antibodies generated from a hybridoma cell line are uniform and

chemically identical. These monoclonal antibodies originate from a single parental B-cell clone, ensuring high specificity. In this technique, B-lymphocytes are fused with myeloma cells in vitro. While myeloma cells rely on de novo DNA synthesis, B-lymphocytes utilize the salvage pathway for DNA replication. A crucial enzyme in this pathway is Hypoxanthine-Guanine Phosphoribosyl Transferase (HGPRT). When these cells are cultured in a Hypoxanthine-Aminopterin-Thymidine (HAT) medium, de novo DNA synthesis is inhibited, leading to the death of unfused myeloma cells. Only B-lymphocytes and successfully fused hybrid cells, known as hybridomas, survive. Hybridoma cells continue to grow because they inherit the HGPRT gene from B-lymphocytes, which lacks in myeloma cells.

Production of Monoclonal antibodies involve following steps:

Immunization

Isolation of B-lymphocytes

Preparation of myeloma cell lines

Cell fusion

Selection of Hybridomas

Screening of Hybridoma Cells

Cloning and Propagation of Hybridoma cells.

Procedure: The production of monoclonal antibodies follows a multi-step procedure. First, laboratory mice are immunized with a selected antigen to stimulate B-lymphocyte production. After sufficient immune response is achieved, the mice are euthanized, and the spleen is harvested to extract B-lymphocytes that produce the desired antibodies [20].



Figure 4. Production of monoclonal antibodies using Hybridoma technology

These B-lymphocytes are subsequently fused with myeloma cells that have been pre-treated with 8-azaguanine. The hybridoma cells formed are incubated in a hypoxanthine-aminopterin-thymidine (HAT) medium, which selectively supports cells containing active hypoxanthine-guanine phosphoribosyl transferase (HGPRT) genes [53]. Surviving hybridoma cells are subsequently screened using techniques such as ELISA or RIA to identify those that generate the target antibodies.

Once the desired hybridomas are identified, they are cloned and expanded in large culture flasks or vessels using either in vitro or in vivo methods. The hybridoma cells are kept in culture media to continue the production of monoclonal antibody. They can be preserved by freezing in liquid nitrogen at different cloning stages [22]. This approach facilitates the generation of monoclonal antibodies with precise epitope specificity, making them valuable for both therapeutic and diagnostic
applications.

Applications of Monoclonal antibodies

Monoclonal antibody (mAb) therapies are emerging as a powerful tool in both diagnostics and therapeutics due to their high specificity in recognizing and binding to various proteins. They are widely utilized for detecting biomarkers such as hormones, vitamins, cytokines, allergens, tumour markers, and infection-related indicators. In clinical applications, monoclonal antibodies serve essential roles in disease diagnosis, drug development, and as therapeutic agents. They are particularly significant in treating cancer, chronic inflammatory conditions, and infectious diseases, making them one of the most rapidly expanding sectors in biopharmaceuticals.

Beyond conventional uses, monoclonal antibodies contribute to personalized medicine by allowing healthcare providers to monitor patient responses to treatments. They are marketed for various diseases, including cancer, autoimmune disorders, asthma, multiple sclerosis, and osteoporosis. Ongoing research is also investigating their potential effectiveness in treating central nervous system disorders, metabolic diseases such as diabetes, and even migraines.

Therapeutically, monoclonal antibodies can target specific antigens on tumor and cancer cells, facilitating the precise delivery of therapeutic agents like radioactive materials, cytokines, toxins, or drugs. These immunoconjugates, which link antibodies to secondary molecules, act as direct cell-killing agents or release therapeutic compounds within cells, improving treatment accuracy and effectiveness across various diseases.

1. **1. Antibodies in pulmonary diseases:**

Chronic respiratory diseases (CRDs), including conditions such as asthma, respiratory allergies and chronic obstructive pulmonary disease (COPD), continue to present significant health challenges. These conditions involve complex

signalling pathways and various biomarkers, leading many patients to require antibody-based treatments. Traditional therapies often fail to adequately control airway inflammation. With COPD projected to become the third leading cause of death globally, the need for targeted treatment strategies has become increasingly critical.

Chemokines and cytokines are essential mediators in the development and progression of COPD, making monoclonal antibodies (mAbs) a promising therapeutic option. Biological treatments, especially mAbs that target specific inflammatory pathways, have shown potential in improving patient outcomes [23]. For instance, omalizumab, which targets IgE, has demonstrated effectiveness in managing moderate-to-severe allergic asthma [38]. Similarly, Benralizumab, which acts on IL-5Rα, is beneficial for patients with severe eosinophilic asthma [24,37]. Dupliumab can target IL-4 and IL-13, demonstrating effectiveness in individuals with asthma and high eosinophil counts [48].

Additionally, nanomedicine is emerging as a promising approach to enhance drug stability and bioavailability [57,58]. Innovations in imaging, such as MRI utilizing iron oxide nanoparticles, allow for non-invasive tracking of macrophage activity in the lungs. This advancement provides valuable insights into inflammation and helps guide treatment decisions. By integrating advanced therapeutic options with cutting-edge diagnostic tools, researchers aim to develop a more effective and comprehensive strategy for managing CRDs.

2. Antibodies in Cancer Treatment:

The discovery of novel molecular targets in cancer therapy has driven the development of therapies based on monoclonal antibodies. The tumour microenvironment, consisting of tumour cells, immune cells, and the extracellular matrix, presents numerous potential targets for these therapeutic antibodies. Monoclonal antibodies can function through several mechanisms, such as inducing direct tumor cell death, facilitating antibody-dependent cellular cytotoxicity (ADCC), and activating complement-dependent cytotoxicity (CDC). Furthermore, monoclonal antibodies can be conjugated with nanoparticles to enable the precise delivery of therapeutic agents, including anticancer cytostatic drugs, enhancing specificity and therapeutic efficiency [22].

Recent research has demonstrated the potential of integrating nanoparticles with monoclonal antibodies for cancer treatment. Engineered nanoparticles can selectively target the malignant cells, improving treatment effectiveness and minimizing adverse effects. furthermore, monoclonal antibodies can enhance the immune system’s capacity to recognize and eliminate tumour cells while also acting as targeted delivery systems for cancer therapies [55].



Figure 5. Core Applications of Monoclonal Antibodies

In metastatic cancers, disruptions in immune cell signalling and proliferation can result in immunosuppression. Monoclonal antibodies such as nivolumab are designed to target specific receptors involved in immune regulation, helping to counteract immunosuppressive effects and stimulate a robust immune response against tumours [56]. Newly emerging therapeutic strategies, including antibody-drug conjugates (ADCs) and bispecific antibodies, have shown potential in cancer treatment. For example, trastuzumab-emtansine [40], an ADC targeting the HER2 receptor, has proven effective in managing invasive breast cancer [59,60]. Rituximab has significantly enhanced the treatment outcomes for aggressive forms of non-Hodgkin's lymphoma (NHL). It was first approved by the U.S. Food and Drug Administration in 1997 Evaluation of Medicinal Products in 1998. through multiple mechanisms discussed earlier [51].

European Agency for the Denosumab, a monoclonal antibody effectively reduces skeletal complications associated with cancer treatments [50].

3. Antibodies in Haematological Diseases

Monoclonal antibodies have significantly revolutionized the treatment of haematological disorders, particularly in haematology and oncology. Rituximab, an innovative monoclonal antibody targeting the CD20 antigen on B lymphocytes, has set the foundation for further anti-CD20 treatments.[25] Despite targeting the same antigen, these antibodies eliminate B cells through multiple mechanisms discussed earlier [26].

Recent advancements have broadened the application of monoclonal antibodies in haematology. Emicizumab, a bispecific antibody, has revolutionized haemophilia A

treatment by mimicking factor VIII activity, thereby improving clot formation [41]. Additionally, the 2019 approval of crizanlizumab marked a breakthrough in sickle cell disease management by preventing Vaso-occlusive crises. By blocking the adhesion of sickle cells to vascular endothelium, crizanlizumab significantly reduces these painful episodes while minimizing adverse effects.

Future research is focused on enhancing the availability and effectiveness of monoclonal antibody therapies in haematology. Ongoing efforts aim to refine existing treatments and develop novel therapeutic options to improve patient outcomes.

4. Antibodies in Cardiovascular Diseases

Cardiovascular diseases (CVD) continue to be the leading cause of mortality globally and is frequently associated with atherosclerosis. The breakdown of atherosclerotic plaques can cause blockages in arteries, raising the risk of strokes and heart attacks. Common risk factors for cardiovascular diseases include high blood pressure, high cholesterol levels, diabetes, and persistent inflammation [5,71].

Statins are widely used to manage high cholesterol levels; however, they come with certain drawbacks. Some patients are resistant to statins, while their efficacy is limited in individuals with homozygous familial hypercholesterolemia or those who are statin-intolerant. The use of statins can cause side effects like myalgia (muscle pain) and in rare instances, can lead to serious muscle degradation known as rhabdomyolysis [27]. As an alternative, monoclonal antibody therapies have shown promise in managing cholesterol levels and reducing inflammation. Alirocumab, a PCSK9 inhibitor, effectively lowers LDL cholesterol without impacting VLDL or triglyceride levels [52]. Evinacumab, which targets ANGPTL3, facilitates the breakdown of triglycerides and other circulating lipids [54]. Canakinumab, an IL-1β inhibitor, helps to control inflammation and presents a potential therapeutic strategy for CVD management. Furthermore, prolonged treatment with canakinumab has been associated with a reduced incidence of anaemia in patients who initially did not have the condition [5].

5. Antibodies for Infectious Diseases

Monoclonal antibody development has garnered widespread attention, particularly for its role in combating infectious diseases such as HIV, tuberculosis, and malaria. One notable breakthrough in this field was the approval of palivizumab, a humanized IgG1-derived antibody, as the first monoclonal antibody treatment for respiratory syncytial virus (RSV), a primary contributor to lower respiratory tract infections in infants and young children [28].

Palivizumab functions by binding to the viral F protein, preventing the virus from attaching to and fusing with host cells. Since no RSV vaccines are currently available, palivizumab

remains the only preventive treatment, significantly reducing RSV-related hospitalizations [29].

In the treatment of infectious diseases, monoclonal antibody therapy offers the unique benefit of enabling the collection of human immunoglobulins from infected individuals, which can then be utilized for therapeutic interventions or research. Ansuvimab, an FDA-approved monoclonal antibody, is used to treat Ebola virus infections by blocking viral membrane fusion and entry into host cells [43].

To date, only a limited number of monoclonal antibodies, such as raxibacumab, obiltoxaximab, and ibalizumab, have received FDA approval for treating infectious diseases [5,61]. Ongoing research seeks to expand the use of monoclonal antibodies in vaccine development and provide new treatment options for previously untreatable infections.

6. Antibodies for Neurological Disorders

Monoclonal antibody-based therapies have revolutionized the management approach of neurological and neuro-inflammatory disorders. Multiple sclerosis (MS) is a long-term autoimmune disorder characterized by immune-driven inflammation that disrupts the central nervous system [30,44]. These therapies have proven effective in treating MS by targeting immune responses. For instance, natalizumab works by binding to integrins, preventing activated T-cells from crossing the blood-brain barrier, thereby reducing inflammation and slowing disease progression [31,62].

Several other monoclonal antibodies, including alemtuzumab, daclizumab, rituximab, ocrelizumab, and ofatumumab [32,63], have shown efficacy in treating relapsing-remitting multiple sclerosis (RRMS). These antibodies target specific receptors, leading to the depletion of lymphocytes or B-cells, which play a role in the disease's progression [61].

Alzheimer’s disease poses a major treatment challenge due to the buildup of amyloid-beta (Aβ) plaques and the formation of neurofibrillary tangles. Existing treatments primarily address symptoms without altering disease progression. Aducanumab, a human monoclonal antibody, offers a promising approach by selectively targeting and reducing both soluble and insoluble Aβ aggregates in the brain, potentially slowing disease advancement [33].

7. 7. Antibodies for Renal diseases

Rituximab, a chimeric monoclonal antibody, has been effective in treating various kidney diseases by specifically targeting the CD20 receptor on B-cells. It has shown particular benefits in conditions such as membranoproliferative glomerulonephritis (MPGN) and lupus nephritis [34,63]. Additionally, it has been beneficial in reducing proteinuria in certain renal conditions and minimizing steroid dependence in patients with idiopathic nephrotic syndrome.

Other monoclonal antibodies, including adalimumab and ofatumumab, have also proven to be useful in lowering proteinuria. However, some monoclonal antibody therapies carry the risk of renal complications, such as hypertension and proteinuria. Bevacizumab, for instance, has been associated with these adverse effects. Similarly, cetuximab and panitumumab, which target the HER-family of receptors [39], can cause electrolyte imbalances, particularly hypomagnesemia and hypokalaemia, due to their nephrotoxic effects on renal tubules. Cetuximab, in particular, has been linked to renal tubular acidosis, while rituximab has been reported to contribute to acute kidney injury in cases of tumour lysis syndrome. Recognizing and managing the possible side effects of monoclonal antibody therapies is essential, particularly for patients with pre-existing kidney conditions [35]. Additionally, some monoclonal antibodies, such as panitumumab and cetuximab, have been associated with electrolyte imbalances due to their toxic effects on renal tubules. To enhance patient safety, it is important to closely monitor these adverse effects and develop treatment plans that mitigate potential risks [63]. A comprehensive understanding of these complications can help create safer and more effective therapeutic approaches.

8. Antibodies for Gastrointestinal Pathologies

Elevated tumour necrosis factor (TNF) levels in patients with inflammatory bowel disease (IBD) contribute to intestinal inflammation, causing tissue damage and interfering with normal immune function. To counteract this, the FDA has approved two TNF inhibitors, infliximab and adalimumab, to treat moderate-to-severe Crohn's disease and ulcerative colitis [36,46].

Infliximab has been shown to support mucosal healing and sustain symptom reduction in both conditions, with a favourable safety profile for long-term use [64,65]. Certolizumab pegol, another FDA-approved therapy for Crohn's disease, is a pegylated anti-TNF fragment designed to reduce immunogenicity. Additionally, anti-IL5 monoclonal antibodies such as mepolizumab and reslizumab, originally developed for eosinophilic asthma, have shown potential in managing eosinophilic esophagitis [5,63].

8. 9. Antibodies for Autoimmune Diseases

Autoimmune disorders such as rheumatoid arthritis (RA) arise from immune system dysfunction, leading to cells and tissue damage. Rheumatoid arthritis (RA) is characterized by chronic inflammation and synovitis, leading to flares of polyarthritis and joint pain. Although the exact mechanism is not clearly understood, pro-inflammatory mediators like IL-6, IL-1, and TNF contribute to the disease's progression. Due to the unique variations in immune system dysfunction among individuals, managing RA remains a complex challenge.

Treatment usually begins with disease-modifying anti-rheumatic drugs (DMARDs)

such as methotrexate. However, if patients fail to respond to traditional DMARDs, biologic DMARDs, including monoclonal antibodies, offer an alternative therapeutic option. Clinical trials have demonstrated that combining biologic therapies with traditional DMARDs leads to improved treatment outcomes. Castleman's disease is a rare condition characterized by abnormal lymphocyte overgrowth with an unclear underlying cause. However, Interleukin-6 (IL-6) is thought to be involved in its progression. Siltuximab, a chimeric monoclonal antibody (IgG1κ) specifically binds to IL-6 and neutralizes its activity [47].

Since IL-6 overactivity contributes to systemic symptoms in RA, it has become a critical target for therapeutic intervention [5]. Monoclonal antibodies such as tocilizumab and sarilumab, which specifically target the IL-6 receptor, have been shown to effectively reduce systemic symptoms in rheumatoid arthritis (RA). Additionally, TNF inhibitors like infliximab and adalimumab are FDA-approved for RA treatment, though some biological DMARDs may provide better symptom control and improve patient adherence. Adalimumab and Infliximab are widely used monoclonal antibodies for immune-related conditions, demonstrating effectiveness in managing RA, Crohn's disease, and ulcerative colitis [25]. Vedolizumab, a recently FDA-approved selective adhesion molecule inhibitor for treating moderate to severe Ulcerative colitis and crohn's disease, targets a more specific molecule compared to Natalizumab [42].

9. 10. Antibodies for Ophthalmological Disorders

Ranibizumab, a monoclonal antibody, has been found effective in treating retinopathy of prematurity (ROP) by inhibiting vascular endothelial growth factor (VEGF), thereby preventing abnormal retinal blood vessel growth [45].

Similarly, naxitamab, an anti-cancer monoclonal antibody, has shown positive outcomes when combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) for treating relapsed or refractory neuroblastoma [72,73]. This combination has gained FDA approval for use in pediatric patients over one year old and adults with refractory neuroblastoma, providing an advanced therapeutic approach [66].

Future Perspective of Monoclonal antibodies

The rapid growth of the antibody industry highlights its immense potential, benefiting both patients and the companies investing in these treatments. The future of monoclonal antibodies appears promising, driven by advancements in biotechnology, genetic engineering, and **computational modeling techniques**. Emerging therapies, such as bispecific antibodies and antibody-drug conjugates, are expected to

improve treatment efficacy, reduce resistance, and minimize adverse effects [74, 75]. Additionally, antibody fragments offer better tissue penetration, helping to address diseases that were previously difficult to treat.

Current research is focused on addressing challenges related to production and affordability, with an emphasis on developing scalable and cost-effective manufacturing processes. As these therapies become more widely available, they have the potential to revolutionize healthcare, particularly in low- and middle-income countries. Monoclonal antibodies are also becoming a key component of precision medicine, enabling more targeted treatments that improve patient outcomes across various conditions. With the continued growth of personalized medicine, integrating **data-driven biomarker strategies** will further enhance the effectiveness of antibody therapies [78]. However, to fully realize their potential, it is essential to overcome obstacles such as high costs, limited accessibility, and immunogenicity concerns. As research progresses, mAbs are poised to broaden therapeutic options and contribute to improved global healthcare standards [76, 77].

Conclusion

Monoclonal antibodies have revolutionized modern medicine by offering targeted therapies for a wide range of diseases, including cancers, infectious illness, autoimmune disorders, and more. Their precision to precisely target specific antigens has minimized side effects while improving patient outcomes, significantly leading to advancements in diagnostics and therapeutic strategies.

Ongoing research and development are expanding the potential applications of monoclonal antibodies, promising new therapeutic possibilities. Advances in immunology, biology, materials science, and technology are further refining their role in immunoassays, transforming both fundamental research and clinical practice. The integration of monoclonal antibodies into personalized medicine provides a powerful approach to shaping the future of healthcare, offering innovative solutions that improve global well-being. However, addressing current challenges will be essential to fully realizing the potential of these ground breaking therapies.

References

1. Marshell, J.S., Warrington, R., Watson, W. & Kim H.L. (2018). “An introduction to immunology and immunopathology.” Allergy, Asthma & Clinical Immunology, 14(2):49.
2. Altmann, D.M. (2018). "A Nobel Prize-worthy pursuit: cancer immunology and

harnessing immunity to tumor neoantigens". Immunology. 155 (3): 283–284.

3. Quinteros, D.A., Bermudez, J.M., Ravetti, S., Cid, A., Allemandi, D.A. & Palma, S.D. (2017). "Therapeutic use of Monoclonal Antibodies: General aspects and challenges for drug delivery". Nanostructures for Drug Delivery. 807-833.
4. Stern, M.; Herrmann, R. (2005). Overview of Monoclonal Antibodies in Cancer Therapy: Present and Promise. Crit. Rev. Oncol. Hematol. 54, 11–29
5. Sharma, P., Joshi, R.V., Pritchard, R., Xu, K. & Eicher, M.A. (2023). "Therapeutic Antibodies in Medicine." Molecules. 28(6438): 1-44
6. Sutradhar, K.B. & Amin, Md.L.(2014). "Nanotechnology in cancer drug delivery and selective targeting review." ISRN Nanotechnology: 1–12.
7. Gao, Y., Huang, X., Zhu, Y. & Lv, Z. (2018). "A brief review of monoclonal antibody technology and its representative applications in immunoassays." Journal of immunoassay and immunochemistry,39(4):351–364.
8. Rodríguez-Nava, C., Ortuño-Pineda, C., Illades-Aguiar, B., Flores-Alfaro, E., Leyva-Vázquez, M. A., Parra-Rojas, I., del Moral-Hernández, O., Vences-Velázquez, A., Cortés-Sarabia, K., & Alarcón-Romero, L. d. C. (2023). Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer. *Biomedicines*, *11*(6), 1610.
9. Nap, M., Hammarström, M.L., Börmer, O., et al (1992). "Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen." Cancer Res., 52(23):29-39.
10. Salles, G.; Długosz-Danecka, M.; Ghesquières, H.; Jurczak, W. (2021). Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Expert. Opin. Biol. Ther., 21, 455–463
11. Golay, J.; Taylor, R.P. (2020). The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer MAbs. Antibodies, 9, 58.
12. Sulica, A., Morel, R., Metes, D. & Herberman, R.B. (2001) "Ig-Binding Receptors on Human NK Cells as Effector and Regulatory Surface Molecules." Int. Rev. Immunology, 20:371–414.
13. Kamen, L.; Myneni, S.; Langsdorf, C.; Kho, E.; Ordonia, B.; Thakurta, T.; Zheng, K.; Song, A.; Chung, S. (2019). A Novel Method for Determining Antibody-Dependent Cellular Phagocytosis. J. Immunol. Methods, 468, 55–60.
14. Bernett MJ, Karki S, G Moore GL, Leung IWL, Chen H, Pong E, Nguyen DHT, Jacinto J, Zalevsky J, Muchhal US, et al. Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions. J Mol Biol 2010; 396(5):1474–1490.

15. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs 2010; 2(3): 256–265
16. . Steinitz M. Human Monoclonal Antibodies. in Methods in molecular biology (Clifton, N.J.), 2014; 1060: 111–22.
17. Chandel P, Harikumar SL. Pharmaceutical monoclonal antibodies: Production, guidelines to cell engineering and applications. Int J Pharm Pharm Sci 2013; 5(2):13– 20.
18. Mahmuda, A. et al. (2017). "Monoclonal antibodies: A review of therapeutic applications and future prospects." Tropical Journal of Pharmaceutical Research, 6(3): 713-722.
19. Milstein, C. (1999)."The hybridoma revolution: an off shoot of basic research". Bioassays.2(11): 966–973.
20. Ganguly, S. & Wakchaure, R. (2016). "Hybridoma technology: a brief review on its diagnostic and clinical significance." Pharmaceutical Biological Evaluation. 3(6):554– 555.
21. Mitra S, Tomar PC. (2021). Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol, 19(1):159.
22. Praetorius, N.P. & Mandal, T.K. (2007). "Engineered nanoparticles in cancer therapy." Recent Pat. Drug Delivery Formulation. 1(1): 37–51.
23. Sécher, T.; Guilleminault, L.; Reckamp, K.; Amanam, I.; Plantier, L.; Heuzé-Vourc'h, N. (2018). Therapeutic Antibodies: A New Era in the Treatment of Respiratory Diseases? Pharmacol. Ther, 189, 149–172.
24. Agache, I.; Rocha, C.; Beltran, J.; Song, Y.; Posso, M.; Solà, I.; Alonso-Coello, P.; Akdis, C.; Akdis, M.; Canonica, G.W.; et al (2020). Efficacy and Safety of Treatment with Biologicals (Benralizumab, Dupilumab and Omalizumab) for Severe Allergic Asthma: A Systematic Review for the EAACI Guidelines—Recommendations on the Use of Biologicals in Severe Asthma. Allergy, 75, 1043–1057.
25. Ghosh, K.; Ghosh, K, (2022). Monoclonal Antibodies Used for the Management of Hemataological Disorders. Expert Rev. Hematol, 15, 443–455.
26. Rougé, L.; Chiang, N.; Steffek, M.; Kugel, C.; Croll, T.I.; Tam, C.; Estevez, A.; Arthur, C.P.; Koth, C.M.; Ciferri, C.; et al (2020). Structure of CD20 in Complex with the Therapeutic Monoclonal Antibody Rituximab. Science, 367, 1224–1230
27. Fitchett, D.H.; Hegele, R.A.; Verma, S. (2015). Statin Intolerance. Circulation, 131, e389–e391
28. Young, M.; Smitherman, L. (2021). Socioeconomic Impact of RSV Hospitalization. Infect. Dis. Ther., 10, 35–45.
29. Garegnani, L.; Styrmisdóttir, L.; Rodriguez, P.R.; Liquitay, C.M.E.; Esteban, I.; Franco, J.V. (2021). Palivizumab for Preventing

Severe Respiratory Syncytial Virus (RSV) Infection in Children. Cochrane Database Syst. Rev., 11, CD013757

30. Garg, N.; Smith, T.W. (2015). An Update on Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis. Brain Behav, 5, e00362.
31. Bates, D.; Bartholomé, E. (2012). Treatment Effect of Natalizumab on Relapse Outcomes in Multiple Sclerosis Patients despite Ongoing MRIActivity. J. Neurol. Neurosurg. Psychiatry, 83, 55–60.
32. Rommer, P.S.; Dudesek, A.; Stüve, O.; Zettl, U. (2014). Monoclonal Antibodies in Treatment of Multiple Sclerosis. Clin. Exp. Immunol., 175, 373–384.
33. Rostagno, A.A. (2023). Pathogenesis of Alzheimer's Disease. Int. J. Mol. Sci., 24, 107.
34. Santoro, D.; Pellicanò, V.; Visconti, L.; Trifirò, G.; Cernaro, V.; Buemi, M. (2015).Monoclonal Antibodies for Renal Diseases: Current Concepts and Ongoing Treatments. Expert Opin. Biol. Ther. 15, 1119–1143.
35. Abbas, A.; Mirza, M.M.; Ganti, A.K.; Tendulkar, K. (2015). Renal Toxicities of Targeted Therapies. Target. Oncol, 10, 487–499.
36. Liang, S.; Dai, J.; Hou, S.; Su, L.; Zhang, D.; Guo, H.; Hu, S.; Wang, H.; Rao, Z.; Guo, Y.; et al. (2013). Structural Basis for Treating Tumor Necrosis Factor (TNF)-Associated Diseases with the Therapeutic Antibody Infliximab. J. Biol. Chem. 288, 13799–13807.
37. Kavanagh, J.E., Hearn, A.P., Dhariwal, J., d'Ancona, G., Douiri, A., et al. (2021). "Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma." Chest,159: 496–506.
38. Pelaia, C., Calabrese, C., Terracciano, R., de Blasio, F., Vatrella, A. & Pelaia, G. (2018). Ee"Omalizumab, the First Available Antibody for Biological Treatment of Severe Asthma: More than a Decade of Real-Life Effectiveness." Ther. Adv. Respir. Dis., 12
39. Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., Jiang, L. & Ye, L. (2021). "Cetuximab Promotes RSL3-Induced Ferroptosis by Suppressing the Nrf2/HO-1 Signalling Pathway in KRAS Mutant Colorectal Cancer." Cell Death Dis., 12,:1079.
40. Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.-Y.; Diéras, V.; Guardino, E.; et al. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med., 367: 1783–1791.
41. Oldenburg, J.; Mahlangu, J.N.; Kim, B.; Schmitt, C.; Callaghan, M.U.; Young, G.; Santagostino, E.; Kruse-Jarres, R.; Negrier, C.; Kessler, C.; et al. (2017). "Emicizumab Prophylaxis in Hemophilia A with Inhibitors." The New England Journal of Medicine., 377, 809–818.
42. Ha, C.; Kornbluth, A. Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterol. Hepatol. 2014, 10, 793–800.

43. Lee, A. “Ansuvimab: First Approval. Drugs” (2021), 81, 595–598.
44. Khoy, K.; Mariotte, D.; Defer, G.; Petit, G.; Toutirais, O. & Le Mauff, B. (2020). “Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.” Frontiers in Immunology.. 11, 549842.
45. Dhoot, D.S. & Kaiser, P.K. (2012). “Ranibizumab for Age-Related Macular Degeneration.” Expert Opinion on Biological Therapy. 12, 371–381
46. Hemperly, A.; Vande Casteele, N. (2018). Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.” Clinical Pharmacokinetics. 57, 929–942.
47. Barquero, N. (2015). “Siltuximab: A New Option for the Management of Castleman’s Disease.” Drugs of Today. 51, 21–28.
48. Beck, L.A.; Thaçi, D.; Hamilton, J.D.; Graham, N.M.; Bieber, T.; Rocklin, R.; Ming, J.E.; Ren, H.; Kao, R.; Simpson, E.; et al. (2014). “Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis.” The New England Journal of Medicine.” 371, 130–139.
49. Imel, E.A. (2021). “Burosumab for Pediatric X-Linked Hypophosphatemia.” Current Osteoporosis Report. 19, 271–277.
50. Dell’Aquila, E.; Armento, G.; Iuliani, M.; Simonetti, S.; D’Onofrio, L.; Zeppola, T.; Madaudo, C.; Russano, M.; Citarella, F.; Ribelli, G.; et al. (2020). “Denosumab for Cancer- Related Bone Loss.” Expert Opinion on Biological Therapy. 20, 1261–1274.
51. Griffin, M.M.; Morley, N. Rituximab in the Treatment of Non-Hodgkin’s Lymphoma—A Critical Evaluation of Randomized Controlled Trials. Expert Opin. Biol. Ther. 2013, 13, 803–811.
52. Räber, L.; Ueki, Y.; Otsuka, T.; Losdat, S.; Häner, J.D.; Lonborg, J.; Fahrni, G.; Iglesias, J.F.; van Geuns, R.-J.; Ondracek, A.S.; et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA 2022, 327, 1771–1781.
53. Ghosh S, Ansar W. (2013). Monoclonal Antibodies: A Tool in Clinical Research. Indian J Clin Med. 4: 9–12.
54. Gao, Y.; Zhang, B.; Yang, J. Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia. Expert Rev. Clin. Pharmacol. 2022, 15, 139–145.
55. Carter P. (2001). Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. Nov;1(2):118-29. doi: 10.1038/35101072. PMID: 11905803.
56. Koppolu, V.; Rekha Vasigala, V.K.(2 0 1 8) . Checkpoint Immunotherapy by Nivolumab for Treatment of Metastatic Melanoma. J. Cancer Res. Ther. 14, 1167–1175.

57. Card, J.W., Zeldin, D.C., Bonner, J.C., Nestmann, E.R., (2008). Pulmonary applications and toxicity of engineered nanoparticles. Am. J. Physiol. Lung Cell. Mol. Physiol. 295 (3), L400–L411.
58. Mansour, H.M., Rhee, Y.S., Wu, X. (2009). Nanomedicine in pulmonary delivery. Int. J. Nanomedicine 4, 299–319.
59. Montazeri, H. A., Shahin, M., Brocks, D.R., Lavasanifar, A., (2008). Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin. Pharmacokinet. 47, 619–634.
60. Miyano, T., Wijagkanalan, W., Kawakami, S., Yamashita, F., Hashida, M., (2010). Anionic amino acid dendrimer-Trastuzumab conjugates for specific internalization in HER2-positive cancer cells. Mol. Pharm. 7 (4), 1318–1327.
61. Singh, S., Tank, N. K., Dwivedi, P., Charan, J., Kaur, R., Sidhu, P., & Chugh, V. K. (2018). Monoclonal antibodies: A review. Current Clinical Pharmacology, 13(2), 85–99.
62. Clerico, M.; Artusi, C. A.; Liberto, A. D.; Rolla, S.; Bardina, V.; Barbero, P.; Mercanti, S. F. D. & Durelli, L. (2017). Natalizumab in Multiple Sclerosis: Long-Term Management. Int. J. Mol. Sci. , 18 (5), 940.
63. Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023). Therapeutic antibodies in medicine. Molecules, 28(18), 6438.
64. Hanauer S. B, Feagan B. G, Lichtenstein G. R., Mayer L. F., Schreiber S., Colombel J. F., Rachmilewitz D, Wolf D. C., Olson A., Bao W., et al. (2002). Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 359(9317):1541–1549.
65. Fidder, H., Schnitzler, F., Ferrante, M., Noman, M., Katsanos, K., Segaert, S., Henckaerts, L., Van Assche, G., Vermeire, S. & Rutgeerts, P. (2009). 'Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study', Gut, vol. 58, pp. 501–508.
66. Lee, A., & Shirley, M. (2021). Ranibizumab: A review in retinopathy of prematurity. Paediatric Drugs, 23, 111–117.
67. Lin, W., Kurosawa, K., Murayama, A., Kagaya, E., & Ohta, K. (2011). B-cell display-based one-step method to generate chimeric human IgG monoclonal antibodies. Nucleic Acids Research, 39(3), 1–10.
68. Mak, T. M., Hanson, B. J., & Tan, Y. J. (2014). Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades. Antiviral Research, 107(1), 76–83.
69. Bakema, J. E., & van Egmond, M. (2014). Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Current Topics in Microbiology and Immunology, 382, 373–392.
70. Wang, S. (2011). Advances in the production of human monoclonal antibodies. Antibody Technology Journal, 1(1), 1–4.
71. Sahebkar, A., & Watts, G. F. (2013). New therapies targeting ApoB metabolism for

high-risk patients with inherited dyslipidaemias: What can the clinician expect? Cardiovascular Drugs and Therapy, 27(6), 559–567.

72. Markham, A. (2021). Naxitamab: First approval. Drugs, 81(3), 291–296. https://doi.org/10.1007/s40265-021-01471-0

73. Kaushal, M., Razak, A., Patel, W., Pullattayil, A. K., & Kaushal, A. (2021). Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: A systematic review and meta-analysis. Journal of Perinatology, 41(6), 1225–1235. https://doi.org/10.1038/s41372-021-01016-9.

74. Hosseini, S. S., Khalili, S., Baradaran, B., Bidar, N., Shahbazi, M.-A., Mosafer, J., Hashemzaei, M., Mokhtarzadeh, A., & Hamblin, M. R. (2021). Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. International Journal of Biological Macromolecules, 167, 1030–1047. https://doi.org/10.1016/j.ijbiomac.2020.11.066.

75. Choi, Y. (2022). Artificial intelligence for antibody reading comprehension: AntiBERTa. Patterns, 3(100535). https://doi.org/10.1016/j.patter.2022.100535.

76. June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361–1365. https://doi.org/10.1126/science.aar6711.

77. June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. The New England Journal of Medicine, 379(1), 64–73. https://doi.org/10.1056/NEJMra1706169.

78. Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020). Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 27(1), 1-30. https://doi.org/10.1186/s12929-019-0592-z